Revelation Biosciences Inc. (REVB) is preparing to showcase new clinical data that could mark an important step forward in the treatment of kidney disease. The company announced that findings from its PRIME study will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026), scheduled to take place in San Diego on March 29, 2026.
The PRIME study evaluated Gemini, Revelation's investigational therapy designed to rebalance the innate immune response in patients with stage 3 and 4 chronic kidney disease. According to the company, Gemini successfully normalized hyperinflammation and restored immune competence, outcomes that could have significant implications for both acute kidney injury (AKI) and chronic kidney disease (CKD).
https://www.nasdaq.com/articles/revelation-bio-share-new-data-prime-study-gemini-march
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.